A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
Recruiting · NCT07743671 · Registry updated 2026-09-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT) | Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, cardiovascular disorder, hematologic disorder, hemorrhagic disease, hereditary hemorrhagic telangiectasia, telangiectasis, vascular disorder, vascular hemostatic disease, vascular malformation | Recruiting | Phase 3 | 2026-09-17 | NCT07743671 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Vaderis Therapeutics AG | 3 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Innovative Hematology, Inc., | Indianapolis | United States | 1 |
| Mayo Clinic | Rochester | United States | 664 |
| The University of Chicago Medical Center (UCMC) | Chicago | United States | 11 |
| Washington University School of Medicine | St Louis | United States | 895 |